|Platelet BioGenesis Inc.
Platelet BioGenesis is a biotechnology company that is making human platelets from induced pluripotent stem cells.
Speaking Up in Support of Federally Funded Research
November 7, 2016 CAMBRIDGE, Mass. – Platelet BioGenesis, a biotech startup developing a method for producing life-saving platelets without the need for human donations, is excited to announce the launch of its newly redesigned website, www.plateletbiogenesis.com!
October 10, 2016 CAMBRIDGE, Mass. – BWH asks Dr. Thon how his role at the Brigham has helped accelerate translational research.
August 19, 2016 CAMBRIDGE, Mass. – Platelet BioGenesis, a biotech startup developing a method for producing life-saving platelets without the need for human donations, is excited to announce that Dr. Philip Reilly and Mr. William (Bill) Nyhan have joined the company’s Board of Directors.
July 14, 2016 CAMBRIDGE, Mass. – Platelet BioGenesis, a biotech startup developing a method for producing life-saving platelets without the need for human blood-bank donations, announced today that it will be expanding its laboratory to the Venture Development Center (VDC) at the University of Massachusetts, Boston.
May 9, 2016 CAMBRIDGE, Mass. – Amgen (NASDAQ: AMGN) and LabCentral announced today that Platelet BioGenesis is an Amgen’s 2016 winner of the highly competitive Golden Ticket award, which underwrites the cost of a lab bench for a Platelet BioGenesis scientist in LabCentral’s open lab for one year.
May 4, 2016 CAMBRIDGE, Mass. – Platelet BioGenesis, a biotech startup developing a method for producing life-saving platelets without the need for human blood-bank donations, announced today that it has received a Small Business Innovation Research (SBIR) grant valued at $1.5 million from the National Heart, Lung, and Blood Institute (NHLBI).
April 7, 2016 CAMBRIDGE, Mass. – Platelet BioGenesis, a biotech startup developing a method for producing life-saving platelets without the need for human blood-bank donations, won first place in a business plan competition co-hosted by BioSciKin, Simcere, Healthcare Executive Magazine, Firestone Investing, and MassBio. Platelet BioGenesis beat out 130 startups in the US for a cash prize of $30K and a trip to Shanghai, China to pitch in front of a panel of distinguished judges and investors.
Interview: Highlighting the Achievements of McMaster Graduates Dr. Jonathan Thon is working on ways to boost platelet production in the lab using a bio-mimetic human platelet bioreactor.
May 26, 2015 WALTHAM, Mass. – The Massachusetts Life Sciences Center (MLSC), a quasi-public agency charged with implementing the state’s 10-year, $1-billion Life Sciences Initiative, announced today the awarding of over $2 million in Milestone Achievement Program (MAP) grants to twelve early-stage life sciences companies, including Platelet BioGenesis. This is the first round of grants awarded under the newly established MAP program.
Apr 10, 2015 Every year in the U.S., nearly 2.2 million platelet units from donors are transfused to treat patients undergoing chemotherapy or surgery. But increasing demand, a short shelf life and risk of contamination keep platelets in tight supply. Now, a new way to generate them could radically transform how we deal with the shortage.
Feb 12, 2015 Their research focuses on how blood platelets, which function as the band-aids of the bloodstream, are produced from megakaryocyte precursor cells. He’s now taking his team to new levels by bringing their work to the clinical and commercial world. He shares his entrepreneurial journey with other academic researchers who have similar interest in bringing their own science to the business world.
Jan-Feb, 2015 Discover Magazine’s Top 100 Inventions of 2014 – #26. “Bioreactor on a chip” could help meet rising demand for blood transfusions.
July 22, 2014 Scientists at Brigham and Women’s Hospital (BWH) have developed a scalable, next-generation platelet bioreactor to generate fully functional human platelets in vitro. The work is a major biomedical advancement that will help address blood transfusion needs worldwide.
Boston researchers make breakthrough on platelet production
July 2, 2014 With the award, approximately $350,000, Thon hopes to produce a next-generation bioreactor to generate the world’s first donor-independent human platelets. The work is expected to scale platelet production to meet global transfusion needs and support drug development by modeling human bone marrow.
April 21, 2014 When you hear about blood shortages, that doesn’t just mean there’s a shortage of donated red blood cells. It could also mean platelets, a blood component that Sven Karlsson described as Band-Aids of the bloodstream, because they’re necessary for blood clot formation to help stop bleeding. Karlsson is a co-founder and chief financial officer of Platelet BioGenesis, a Boston startup that’s developing a way to produce human platelets in a lab using a microfluidic-based bioreactor.
March 27, 2014 One way of boosting platelet production in the lab is with a microfluidic bioreactor that mimics the physical characteristics of megakaryocytes’ bone marrow environment. Unlike traditional static culture methods for growing megakaryocytes, a platelet bioreactor is built to be structurally similar to bone marrow and exposes the cells to the same shear forces they experience within the real bone marrow environment. It also can act as a platform for studying physical and biochemical influences on platelet production.
January 30, 2014 Dr. Jonathan Thon, a leading researcher in therapies for cardiovascular diseases from Brigham and Women’s Hospital and Harvard Medical School delivers the second keynote address entitled ‘An Impactful Scientific Career’ at the RCSI Human Disease Mapping conference (HDM) which was held from 30th-31st January 2014.
March 5, 2012 Solving the platelet production problem: A microfluidic device that could reproduce the platelet’s developmental milieu in a way that serves both researchers wanting to understand platelet development and the patients in need of lifesaving platelet transfusions.
Members of ash participate in inaugural advocacy leadership institute.
October 12-13, 2011 The American Society of Hematology (ASH) Government Relations, Practice, and Scientific Affairs department two-day political advocacy program.
December 20, 2010 The American Society of Hematology (ASH) announces the 2011 Scholar Award recipients. The program is designed to support hematologists who have chosen a career in research by providing partial salary or other support during the critical period required for completion of training and achievement of status as an independent investigator.
March 9-10, 2013 The Gordon Research Seminar on Cell Biology of Megakaryocytes and Platelets is a unique forum for graduate students, post-docs, and other scientists with comparable levels of experience and education to present and exchange new data and cutting edge ideas.
The focus of this meeting is to bring together young investigators to present their latest innovative work toward advancing our understanding of megakaryocyte and platelet formation and function. Through career oriented presentations and round table discussion with both academic and pharmaceutical leaders in their field, this GRS will also provide young investigators with valuable career advice from experts conducting basic, translational and pharmaceutical research.
June 3, 2013 Brigham and Women’s Hospital Profile.
June 10, 2013 Democratizing research through crowdfunding as a way to complement federal/private grants for funding basic research.
Factual Footage Inc. is a science consulting firm that specializes in the film & television industries.
FFI consults on all forms of media: film, television, theatre, video games, novels & others
FFI consults on all disciplines of science: biology, chemistry, biochemistry, genetics, physics, medical science
Some of the ways they can help:
|Tweets by @JonathanThon
Tweets by @PlateletBioGen